康爱保生丸是依据云南省“国医大师”张震研究员的学术思想及组方理论研制的医疗机构制剂，已在云南省中医药治疗艾滋病试点项目中广泛应用10年，临床疗效受到认可和关注。综合前期研究基础及文献分析，本项目首先开展转录组学筛选研究，应用芯片技术对不同类型HIV/AIDS患者外周血CD4+T细胞中表达异常的lncRNAs的进行筛查及其验证；其次开展开展前瞻性临床研究，观察HAART联用康爱保生丸治疗对HIV/AIDS患者外周血CD4+T细胞中差异表达lncRNAs的影响作用；而后开展生物信息学研究，分析预测治疗过程中患者外周血CD4+T细胞lncRNAs可能富集的生物学信号通路；最后开展信号通路研究，应用液相悬浮芯片系统验证参与调控的生物学信号通路。研究结果可阐释HAART联用康爱保生丸在治疗HIV/AIDS过程中对免疫细胞异常表达lncRNAs及其调控机制，发现新靶点，为临床应用提供依据.

Kang Ai Bao Sheng Wan is a medical institution preparation developed on the basis of the academic thought and formulation theory of researcher Zhang Zhen, a " TCM( traditional Chinese medicine ) master of China"in Yunnan Province.Kang Ai Bao Sheng Wan has been widely used for 10 years in the pilot project of TCM treatment for AIDS in Yunnan Province, and its clinical efficacy has been recognized and focused. Based on the previous research foundation and literature analysis, firstly, chip technology will be applied for screening and verify lncRNAs with abnormal expression in CD4+T cells in HIV/AIDS.Secondly, a prospective clinical study was carried out to observe the effect of HAART combined with Kang Ai Bao Sheng Wan on the differential expression of lncRNAs in CD4+T cells of HIV/AIDS patients. Then, bioinformatics research is carried out to analyze and predict the biological signal pathways that may be enriched by lncRNAs of CD4+T cells in patients' peripheral blood during treatment. Finally, the signal pathway research was carried out, and the biological signal pathway involved in regulation was verified by MilliplexTM EpiQuant. The results of the study can explain the expression and regulatory of lncRNAs on CD4+T cells of HIV/AIDS during the treatment by HAART&Kang Ai Bao Sheng Wan, which is helpful to discover its mechanism and new targets, and provide basis the for TCM&HAART clinical treatment that application and promotion in AIDS.